Vanguard Group Inc. Grows Holdings in Audentes Therapeutics Inc (BOLD)

Vanguard Group Inc. raised its holdings in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 130.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 678,412 shares of the biotechnology company’s stock after acquiring an additional 383,837 shares during the quarter. Vanguard Group Inc. owned approximately 2.45% of Audentes Therapeutics worth $12,978,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp boosted its stake in shares of Audentes Therapeutics by 238.0% during the second quarter. Northern Trust Corp now owns 184,173 shares of the biotechnology company’s stock valued at $3,524,000 after purchasing an additional 129,681 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Audentes Therapeutics by 299.9% during the second quarter. New York State Common Retirement Fund now owns 16,400 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 12,299 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Audentes Therapeutics by 27.1% during the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 3,324 shares in the last quarter. Nationwide Fund Advisors increased its holdings in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Audentes Therapeutics by 459.3% during the second quarter. TIAA CREF Investment Management LLC now owns 64,497 shares of the biotechnology company’s stock valued at $1,234,000 after acquiring an additional 52,965 shares in the last quarter. 78.99% of the stock is owned by institutional investors.

In other Audentes Therapeutics news, SVP David Nagler sold 3,750 shares of the company’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $30.00, for a total transaction of $112,500.00. Following the completion of the sale, the senior vice president now owns 3,750 shares in the company, valued at $112,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Suyash Prasad sold 8,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 766,500 shares of company stock worth $21,568,850. Insiders own 47.30% of the company’s stock.

Audentes Therapeutics Inc (BOLD) traded up $0.05 during midday trading on Wednesday, reaching $27.43. The company had a trading volume of 134,629 shares, compared to its average volume of 148,030. Audentes Therapeutics Inc has a 12 month low of $13.90 and a 12 month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.88). equities analysts anticipate that Audentes Therapeutics Inc will post -3.52 EPS for the current fiscal year.

BOLD has been the topic of several research analyst reports. Bank of America reaffirmed a “buy” rating and set a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. BidaskClub lowered Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Finally, Raymond James Financial assumed coverage on Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Audentes Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $28.29.

TRADEMARK VIOLATION NOTICE: “Vanguard Group Inc. Grows Holdings in Audentes Therapeutics Inc (BOLD)” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/vanguard-group-inc-acquires-383837-shares-of-audentes-therapeutics-inc-bold.html.

Audentes Therapeutics Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply